scholarly journals Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

2019 ◽  
Vol 8 (6) ◽  
pp. 1086-1090
Author(s):  
Yusuke Chihara ◽  
Tadaaki Yamada ◽  
Junji Uchino ◽  
Nobuyo Tamiya ◽  
Yoshiko Kaneko ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document